α-Synuclein: membrane interactions and toxicity in Parkinson's disease
- PMID: 20500090
- DOI: 10.1146/annurev.cellbio.042308.113313
α-Synuclein: membrane interactions and toxicity in Parkinson's disease
Abstract
In the late 1990s, mutations in the synaptic protein α-synuclein (α-syn) were identified in families with hereditary Parkinson's disease (PD). Rapidly, α-syn became the target of numerous investigations that have transformed our understanding of the pathogenesis underlying this disorder. α-Syn is the major component of Lewy bodies (LBs), cytoplasmic protein aggregates that form in the neurons of PD patients. α-Syn interacts with lipid membranes and adopts amyloid conformations that deposit within LBs. Work in yeast and other model systems has revealed that α-syn-associated toxicity might be the consequence of abnormal membrane interactions and alterations in vesicle trafficking. Here we review evidence regarding α-syn's normal interactions with membranes and regulation of synaptic vesicles as well as how overexpression of α-syn yields global cellular dysfunction. Finally, we present a model linking vesicle dynamics to toxicity with the sincere hope that understanding these disease mechanisms will lead to the development of novel, potent therapeutics.
Similar articles
-
α-Synuclein aggregation and modulating factors.Subcell Biochem. 2012;65:109-64. doi: 10.1007/978-94-007-5416-4_6. Subcell Biochem. 2012. PMID: 23225002 Review.
-
Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.Trends Mol Med. 2012 May;18(5):248-55. doi: 10.1016/j.molmed.2012.03.002. Epub 2012 Apr 13. Trends Mol Med. 2012. PMID: 22503115 Review.
-
Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.Prog Brain Res. 2010;183:115-45. doi: 10.1016/S0079-6123(10)83007-9. Prog Brain Res. 2010. PMID: 20696318 Review.
-
Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins.Acta Neuropathol. 2017 Oct;134(4):629-653. doi: 10.1007/s00401-017-1722-x. Epub 2017 May 19. Acta Neuropathol. 2017. PMID: 28527044
-
Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Mov Disord. 2013. PMID: 23390095 Review.
Cited by
-
Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates.J Am Chem Soc. 2013 Feb 27;135(8):2943-6. doi: 10.1021/ja312415q. Epub 2013 Feb 14. J Am Chem Soc. 2013. PMID: 23398174 Free PMC article.
-
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.EMBO J. 2012 Jun 26;31(14):3038-62. doi: 10.1038/emboj.2012.170. EMBO J. 2012. PMID: 22735187 Free PMC article. Review.
-
Protection against Mitochondrial and Metal Toxicity Depends on Functional Lipid Binding Sites in ATP13A2.Parkinsons Dis. 2016;2016:9531917. doi: 10.1155/2016/9531917. Epub 2016 Mar 17. Parkinsons Dis. 2016. PMID: 27073711 Free PMC article.
-
Exploiting Post-mitotic Yeast Cultures to Model Neurodegeneration.Front Mol Neurosci. 2018 Nov 2;11:400. doi: 10.3389/fnmol.2018.00400. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30450036 Free PMC article. Review.
-
E46K-like α-synuclein mutants increase lipid interactions and disrupt membrane selectivity.J Biol Chem. 2019 Jun 21;294(25):9799-9812. doi: 10.1074/jbc.RA118.006551. Epub 2019 May 2. J Biol Chem. 2019. PMID: 31048377 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous